Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure

Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of antidiabetic drugs that have shown favorable effects in heart failure (HF) patients, irrespective the left ventricular ejection fraction (LVEF). Recent studies demonstrated beneficial empagliflozin on cardiac function and structure; however, less is known about dapagliflozin. The purpose current work was to investigate association between use dapagliflozin biomarkers as well structure cohort patients with HF diabetes mellitus (DM). present an observational study included 118 (dapagliflozin group n = 60; control 58) DM. inclusion criteria included: age > 18 years, history DM HF, regardless LVEF, hospitalization for exacerbation within previous 6 months. exclusion were treatment SGLT2i or glucagon-like peptide-1 receptor agonists, GFR< 30 life expectancy < 1 year. evaluation (at baseline, 12 months) clinical assessment, laboratory blood tests echocardiography. Mann–Whitney test used comparison continuous variables two groups, while Friedman’s analysis variance repeated measures variables. Troponin (p 0.001) brain natriuretic peptide (BNP) decreased significantly throughout follow-up period group, but not 0.05 both). LV end-diastolic volume index 0.001 both groups) end-systolic respectively. LVEF increased only whereas global longitudinal strain (GLS) improved impaired 0.021). atrial remained unchanged 0.114). Lastly, mass 0.003) 0.001). Dapagliflozin, SGLT2i, associated reduction reverse remodeling